Free Trial

Pyxis Oncology (PYXS) Stock Price, News & Analysis

Pyxis Oncology logo
$1.25 -0.09 (-6.72%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pyxis Oncology Stock (NASDAQ:PYXS)

Key Stats

Today's Range
$1.17
$1.31
50-Day Range
$1.08
$1.35
52-Week Range
$0.83
$5.39
Volume
592,152 shs
Average Volume
436,145 shs
Market Capitalization
$77.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Moderate Buy

Company Overview

Pyxis Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

PYXS MarketRank™: 

Pyxis Oncology scored higher than 48% of companies evaluated by MarketBeat, and ranked 596th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Pyxis Oncology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pyxis Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pyxis Oncology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pyxis Oncology is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pyxis Oncology has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pyxis Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    11.49% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 18.12%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pyxis Oncology does not currently pay a dividend.

  • Dividend Growth

    Pyxis Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.49% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 18.12%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pyxis Oncology has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.08 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.09% of the stock of Pyxis Oncology is held by institutions.

  • Read more about Pyxis Oncology's insider trading history.
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

PYXS Stock News Headlines

Pyxis Oncology Inc News (PYXS) - Investing.com
A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
See More Headlines

PYXS Stock Analysis - Frequently Asked Questions

Pyxis Oncology's stock was trading at $1.56 at the start of the year. Since then, PYXS shares have decreased by 19.9% and is now trading at $1.25.

Pyxis Oncology, Inc. (NASDAQ:PYXS) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.06.

Pyxis Oncology (PYXS) raised $158 million in an initial public offering on Friday, October 8th 2021. The company issued 10,500,000 shares at a price of $14.00-$16.00 per share.

Pyxis Oncology's top institutional investors include Kingstone Capital Partners Texas LLC (0.05%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy and Jitendra Wadhane.
View institutional ownership trends
.

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
7/28/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PYXS
CIK
1782223
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$5.00
Potential Upside/Downside
+620.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.33 million
Net Margins
N/A
Pretax Margin
-492.35%
Return on Equity
-57.49%
Return on Assets
-45.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.75
Quick Ratio
7.75

Sales & Book Value

Annual Sales
$16.15 million
Price / Sales
4.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.03 per share
Price / Book
0.62

Miscellaneous

Outstanding Shares
61,950,000
Free Float
55,382,000
Market Cap
$77.44 million
Optionable
Optionable
Beta
1.13

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:PYXS) was last updated on 7/28/2025 by MarketBeat.com Staff
From Our Partners